The Health Care Reform Corner – From the editors of "The Pink Sheet" May 26, 2009
What are policymakers and stakeholders in Washington saying and doing about health care reform? In this periodic BioPharma Today feature, the editors of"The Pink Sheet" and "The Pink Sheet" DAILY highlight some of the major developments chronicled in those publications.
Read today's feature...
The Health Care Reform Corner – From the editors of "The Pink Sheet" May 26, 2009
A group of moderate House Democrats introduced legislation on comparative effectiveness research May 19 that includes new language aimed specifically at limiting the influence of CER on physician prescribing.
Introduced by Rep. Kurt Schrader, Ore., the bill is modeled on the comparative effectiveness legislation introduced in the last Congress by Sens. Max Baucus, D-Mont., and Kent Conrad, D-N.D.
Like that legislation, H.R. 2502 would establish a non-governmental institute responsible for managing and guiding health research programs to evaluate and compare the implications and outcomes of two or more health care strategies.
The House legislation also adopts the provisions of the Baucus/Conrad bill barring the CER institute from "mandating coverage, reimbursement or other policies for any public or private payer."
But it adds something more, designed to further ensure that CER findings will not restrict access to medical products. Read the story here…
Not a subscriber? Click on the links below to start a 30-day, risk-free trial:
“The Pink Sheet”– Providing comprehensive weekly biopharma industry insight and analysis for more than 70 years.
“The Pink Sheet” DAILY – immediate biopharma business intelligence from the company and product level up. Interested in a 3-month starter subscription to “The Pink Sheet” DAILY for only $299? Click here to learn more.
